Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
Open Access
- 16 November 2016
- journal article
- review article
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 5 (1) , 1-4
Abstract
Amyloid plaques are pathological hallmarks of Alzheimer’s Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1–42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers.Keywords
This publication has 36 references indexed in Scilit:
- Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β PeptideThe Journal of Neuroscience, 2012
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide ClearanceScience Translational Medicine, 2011
- Alzheimer’s Disease: The Challenge of the Second CenturyScience Translational Medicine, 2011
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNature Reviews Neuroscience, 2009
- APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central NorwayBMC Neurology, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Lack of apolipoprotein E dramatically reduces amyloid β-peptide depositionNature Genetics, 1997
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993